Comparative Pharmacology
Head-to-head clinical analysis: SORIATANE versus TRETINOIN MICROSPHERE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: SORIATANE versus TRETINOIN MICROSPHERE.
SORIATANE vs TRETINOIN MICROSPHERE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Retinoid that binds to nuclear retinoic acid receptors (RARs), modulating gene expression involved in cell proliferation, differentiation, and apoptosis.
Tretinoin microsphere is a retinoid that binds to retinoic acid receptors (RARα, RARβ, RARγ) and retinoid X receptors (RXRα, RXRβ, RXRγ), modulating gene expression involved in cell proliferation, differentiation, and inflammation. It normalizes follicular keratinization, reduces microcomedone formation, and increases epidermal turnover.
Initial: 25-50 mg orally once daily; maintenance: 25-50 mg orally once daily; not to exceed 75 mg/day.
Apply a pea-sized amount (approximately 0.5 g) topically once daily at bedtime to dry skin.
None Documented
None Documented
Terminal elimination half-life of etretinate (active form) is ≈100–125 days due to storage in adipose tissue; clinically relevant for prolonged teratogenicity.
Terminal elimination half-life approximately 0.5–2 hours in terminal phase; longer terminal phase (10–20 hours) observed for 13-cis-retinoic acid metabolite.
Primarily hepatic metabolism; eliminated via feces (≈60%) and urine (≈15%) as metabolites; parent drug not excreted unchanged.
Primarily hepatic metabolism via CYP450 isoforms to polar metabolites; renal excretion accounts for <1% unchanged; biliary/fecal elimination of metabolites is significant (approximately 30-60%).
Category C
Category D/X
Retinoid
Retinoid